BR9915087A - Formulação farmacêutica oral revestida entérica, uso de uma qualidade de hidroxipropil celulose (hpc), processo para a munufatura de uma formulação farmacêutica oral revestida entérica, uso de uma formulação farmacêutica, e, método para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem - Google Patents

Formulação farmacêutica oral revestida entérica, uso de uma qualidade de hidroxipropil celulose (hpc), processo para a munufatura de uma formulação farmacêutica oral revestida entérica, uso de uma formulação farmacêutica, e, método para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem

Info

Publication number
BR9915087A
BR9915087A BR9915087-5A BR9915087A BR9915087A BR 9915087 A BR9915087 A BR 9915087A BR 9915087 A BR9915087 A BR 9915087A BR 9915087 A BR9915087 A BR 9915087A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulation
enteric coated
coated oral
oral pharmaceutical
omeprazole
Prior art date
Application number
BR9915087-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Pontus Bergstrand
Peter Wang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20413180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9915087(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR9915087A publication Critical patent/BR9915087A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
BR9915087-5A 1998-11-05 1999-11-03 Formulação farmacêutica oral revestida entérica, uso de uma qualidade de hidroxipropil celulose (hpc), processo para a munufatura de uma formulação farmacêutica oral revestida entérica, uso de uma formulação farmacêutica, e, método para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem BR9915087A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9803772A SE9803772D0 (sv) 1998-11-05 1998-11-05 Pharmaceutical formulation
PCT/SE1999/001989 WO2000027366A1 (en) 1998-11-05 1999-11-03 Pharmaceutical formulation comprising omeprazole

Publications (1)

Publication Number Publication Date
BR9915087A true BR9915087A (pt) 2001-07-17

Family

ID=20413180

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9915087-5A BR9915087A (pt) 1998-11-05 1999-11-03 Formulação farmacêutica oral revestida entérica, uso de uma qualidade de hidroxipropil celulose (hpc), processo para a munufatura de uma formulação farmacêutica oral revestida entérica, uso de uma formulação farmacêutica, e, método para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem

Country Status (20)

Country Link
US (1) US6428810B1 (de)
EP (1) EP1124539B1 (de)
JP (2) JP5412021B2 (de)
KR (1) KR100627205B1 (de)
CN (1) CN1160062C (de)
AT (1) ATE244002T1 (de)
AU (1) AU774278B2 (de)
BR (1) BR9915087A (de)
CA (1) CA2346988C (de)
DE (1) DE69909316T2 (de)
DK (1) DK1124539T3 (de)
ES (1) ES2201837T3 (de)
HK (1) HK1039070B (de)
IL (2) IL142474A0 (de)
NO (1) NO320056B1 (de)
NZ (1) NZ510993A (de)
PT (1) PT1124539E (de)
SE (1) SE9803772D0 (de)
WO (1) WO2000027366A1 (de)
ZA (1) ZA200103336B (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
ES2168043B1 (es) 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
TWI232761B (en) * 2000-07-01 2005-05-21 Pharmaceutical Ind Tech & Dev Capsule preparation for oral administration and the preparation method thereof
US6418968B1 (en) 2001-04-20 2002-07-16 Nanostream, Inc. Porous microfluidic valves
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
CN100408029C (zh) 2001-09-28 2008-08-06 麦克内尔-Ppc股份有限公司 有镶嵌部分的组合剂型
US20050163846A1 (en) * 2001-11-21 2005-07-28 Eisai Co., Ltd. Preparation composition containing acid-unstable physiologically active compound, and process for producing same
WO2003049693A2 (en) * 2001-12-06 2003-06-19 Wyeth Method and composition for inducing weight loss
US6982080B2 (en) * 2002-03-15 2006-01-03 Wyeth Hydroxyethyl starch—containing polypeptide compositions
EP1545474A1 (de) * 2002-09-16 2005-06-29 Wyeth Formulierungen mit verzögerter freisetzung zur oralen verabreichung eines therapeutischen polypeptid-mittels und anwendungsverfahren daf r
AU2003900096A0 (en) * 2003-01-10 2003-02-20 Nature Vet Orally deliverable pharmaceutical composition protein pump inhibitors
US20040185119A1 (en) * 2003-02-26 2004-09-23 Theuer Richard C. Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency
WO2004089333A2 (en) * 2003-02-28 2004-10-21 Cadila Healthcare Limited A stable benzimidazole formulation
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR045068A1 (es) * 2003-07-23 2005-10-12 Univ Missouri Formulacion de liberacion inmediata de composiciones farmaceuticas
CN1938026A (zh) * 2004-03-26 2007-03-28 卫材R&D管理有限公司 控释制剂及其制造方法
US20050239845A1 (en) * 2004-04-16 2005-10-27 Santarus, Inc. Combination of proton pump inhibitor, buffering agent, and prokinetic agent
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050281876A1 (en) * 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
JPWO2007037259A1 (ja) * 2005-09-29 2009-04-09 エーザイ・アール・アンド・ディー・マネジメント株式会社 生体内での崩壊性を向上させたパルス製剤
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
CN100431526C (zh) * 2005-11-07 2008-11-12 上海艾力斯医药科技有限公司 一种酸敏感型药物的快速崩解片剂
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
EP2068841B1 (de) 2006-10-05 2018-09-26 Santarus, Inc. Neuartige formulierungen von protonenpumpenhemmern und verfahren zu ihrer verwendung
WO2008062320A2 (en) * 2006-10-06 2008-05-29 Eisai R&D Management Co., Ltd Extended release formulations of a proton pump inhibitor
WO2008057802A2 (en) 2006-10-27 2008-05-15 The Curators Of The University Of Missouri Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same
KR101104349B1 (ko) * 2007-09-28 2012-01-16 주식회사 씨티씨바이오 에소메프라졸 함유 약학 조성물
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP2344139A1 (de) 2008-09-09 2011-07-20 AstraZeneca AB Verfahren zur abgabe einer pharmazeutischen zusammensetzung an einen patienten, der diese benötigt
EA201290026A1 (ru) 2009-06-25 2012-07-30 Астразенека Аб Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid)
US20110008432A1 (en) * 2009-06-25 2011-01-13 Pozen Inc. Method for Treating a Patient in Need of Aspirin Therapy
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
CN102631327B (zh) * 2012-05-14 2013-08-28 海南葫芦娃制药有限公司 一种奥美拉唑肠溶微丸及其制备方法
EP3288556A4 (de) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Oral zerfallende zusammensetzungen
JP6967513B2 (ja) * 2015-12-22 2021-11-17 シエル・インターナシヨナル・リサーチ・マートスハツペイ・ベー・ヴエー 溶融ポリカーボネートを生成するための方法
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) 1983-03-04 1983-03-04 Haessle Ab Novel compounds
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) 1993-07-09 1993-07-09 Ab Astra A novel compound form
JP3350054B2 (ja) * 1994-07-08 2002-11-25 アストラゼネカ・アクチエボラーグ 複数単位の錠剤化された剤形▲ｉ▼
SE9600072D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600070D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation

Also Published As

Publication number Publication date
NO20012222D0 (no) 2001-05-04
ES2201837T3 (es) 2004-03-16
SE9803772D0 (sv) 1998-11-05
IL142474A (en) 2007-08-19
AU774278B2 (en) 2004-06-24
PT1124539E (pt) 2003-11-28
HK1039070A1 (en) 2002-04-12
KR100627205B1 (ko) 2006-09-22
WO2000027366A1 (en) 2000-05-18
JP5412021B2 (ja) 2014-02-12
ATE244002T1 (de) 2003-07-15
KR20010075685A (ko) 2001-08-09
NZ510993A (en) 2003-08-29
DE69909316D1 (de) 2003-08-07
CN1325300A (zh) 2001-12-05
NO320056B1 (no) 2005-10-17
EP1124539B1 (de) 2003-07-02
IL142474A0 (en) 2002-03-10
JP2002529397A (ja) 2002-09-10
NO20012222L (no) 2001-07-02
US6428810B1 (en) 2002-08-06
CA2346988C (en) 2009-02-10
HK1039070B (zh) 2003-12-19
JP2012031189A (ja) 2012-02-16
ZA200103336B (en) 2002-07-24
DE69909316T2 (de) 2004-06-03
DK1124539T3 (da) 2003-10-06
EP1124539A1 (de) 2001-08-22
AU1434600A (en) 2000-05-29
CN1160062C (zh) 2004-08-04
CA2346988A1 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
BR9915087A (pt) Formulação farmacêutica oral revestida entérica, uso de uma qualidade de hidroxipropil celulose (hpc), processo para a munufatura de uma formulação farmacêutica oral revestida entérica, uso de uma formulação farmacêutica, e, método para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem
BR9809484A (pt) Formulação farmacêutica oral revestida entérica, processo para a manufatura da mesma, uso de uma qualidade de hidroxipropil metilcelulose (hpmc) de baixa viscosidade, e, processo para o tratamento de doenças gastrointestinais em mamìferos, incluindo o homem.
PT1308159E (pt) Composicao farmaceutica contendo um omeprazole labil a acidos e processo para a sua preparacao
RU99126869A (ru) Фармацевтический препарат омепразола
HUP0201489A2 (hu) Új adagolási forma
DE69023183D1 (de) Rotogranulate und geschmacksabdeckende Überzüge zur Herstellung pharmazeutischer Kautabletten.
ATE380022T1 (de) Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
EE04800B1 (et) Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
BR9605121A (pt) Formulação de dosagem farmecêutica oral processo para a preparação de uma formulação de dosagem farmacêutica oral revestida entericamente processo para inibir a secreção ácida gástrica em mamíferos e no ser human e uso de uma formulação de dosagem farmacêutica oral
CA2315261A1 (en) Oral pharmaceutical extended release dosage form
PT923934E (pt) Formulacao de matriz de libertacao modificada de cefaclor e cefalexina
BR0206515A (pt) Composição de revestimento de pelìcula, revestimento de pelìcula cobrindo um núcleo farmacêutico, formulação farmacêutica, e, processos para preparar uma composição de revestimento de pelìcula, um revestimento de pelìcula, e uma formulação
ATE110379T1 (de) Therapeutisch aktive substituierte benzimidazole und verfahren zu ihrer herstellung.
EP0137442A3 (de) Cephalosporinderivate und Verfahren zu ihrer Herstellung
HUP0203310A2 (hu) Benzimidazolszármazékot tartalmazó stabil gyógyszerkészítmények és eljárás ezek előállítására

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 9/36 (2008.01), A61K 31/4439 (2008.01), A61K

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]